CT-guided 125I Seed Implantation on Treatment of Recurrent Soft Tissue Sarcoma after Multimodal Treatment
L. Lin,J.J. Wang,Y.L. Jiang,N. Meng,S.Q. Tian,R.J. Yang,C. Liu
DOI: https://doi.org/10.1016/j.brachy.2014.02.280
IF: 6.901
2014-01-01
Radiotherapy and Oncology
Abstract:Soft tissue sarcomas are marked by a poor outcome, especially recurrence. This study aimed to explore whether the adoption of interstitial 125I seed implantation in patients with recurrence soft tissue sarcoma after surgery combined with radiation. We conducted a retrospective review of 31 patients (median age, 64 years; range, 6-79 years; 14 male, 17 female) with local recurrence after surgery combined with radiation of soft tissue sarcoma, who underwent 125I seed implantation in our department from 2003 to 2012. Details of tumor volumes were assessed using CT 1 to 2 days prior to seed implantation, and pretreatment planning was received. The seeds were implanted using a Mick applicator (Mick Radio-Nuclear Instruments Inc., Mount Vernon, NY), and the distance between the centers of any 2 seeds was maintained at approximately 1.0 cm. Tumor response was initially evaluated at 4 weeks and thereafter at intervals of 2 to 3 months. Disease status was assessed by physical examination, liver function tests, and full blood and platelet counts. Radiological measurement of disease progression, which included ultrasound examination and CT scans, was performed. All the patients were followed up until expiration. The median followup period, which was measured from the time of seed implantation, was 21 months (range, 3-53 months). All statistical analyses were onducted using SPSS version 19.0 (SPSS, Chicago, IL). The activity of the 125I seeds ranged from 0.5-0.8 mCi (median, 0.7 mCi). The prescribed doses delivered to 90% of the gross tumor volume as defined by treatment planning system using a dose-volume histogram (D90) was 143-184 Gy (median, 170 Gy). The median overall survival time was 34 months (3-43 months), and 1- and 3- year survival rates were 86.3% and 65.3%, respectively. There was no serious complication was observed. Of the 31 patients, 8 (25.8%) patients still alive, 17 (54.8%) died of multi hematogenous metastasis, and 6 (19.4%) patients died of pneumonia. No serious complications were observed following seed implantation. There was no evidence of bone or soft tissue necrosis, carotid rupture, neuropathy, blood vessel damage, or late complications. In conclusion, the results of our study suggest that percutaneous 125I seed implantation is a safe and effective salvage treatment for recurrent soft tissue sarcoma after surgery combined with radiation.